Status:
COMPLETED
Expressive Helping for Stem Cell Transplant Patients
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
National Cancer Institute (NCI)
Lombardi Comprehensive Cancer Center
Conditions:
Stem Cell Transplantation
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Writing for Insight, Strength, and Ease (WISE) Study is a multisite Randomized Controlled Trial (RCT) testing the efficacy of the Expressive Helping (EH) intervention among adults receiving hemato...
Detailed Description
Use of stem cell transplant (mostly for hematologic cancers) is expected to increase 5-fold by 2030, when the number of survivors will reach 500,000. This highly toxic treatment causes a range of acut...
Eligibility Criteria
Inclusion
- Cancer patients
- Age ≥ 18
- English proficient
- Scheduled for allogeneic or autologous transplant at JTCC, LCCC, or RHLCC.
Exclusion
- Current participation in a behavioral intervention targeting symptoms or quality of life
- Cognitive or psychiatric impairment precluding ability to complete informed consent or study procedures
- Literacy limitations precluding completion of a writing study
- Undergoing a tandem transplant where participant is now completing the first of two or more planned transplants
Key Trial Info
Start Date :
March 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 24 2023
Estimated Enrollment :
405 Patients enrolled
Trial Details
Trial ID
NCT03800758
Start Date
March 6 2019
End Date
April 24 2023
Last Update
May 6 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, United States, 20007
2
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States, 60611
3
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601